Sanofi's Aubagio for MS accepted for US review alongside new data boost
This article was originally published in Scrip
Executive Summary
In reporting new data from a pivotal trial of its oral multiple sclerosis therapy, teriflunomide (Aubagio), Sanofi also said that the US FDA has accepted for review the new drug application (NDA) for the product as a potential treatment for relapsing forms of multiple sclerosis (MS). The company added that it is still aiming for a European submission in the first quarter of next year.